Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multicenter Clinical Study (Truce-LB02)

NCT07180212 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT07180212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07180212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multicenter Clinical Study (Truce-LB02)
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 20, 2025
Completion date
November 1, 2027
Enrollment
360 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cystoscopy, liquid biopsy